Abstract: BaCkground: Actinic keratoses are benign intraepithelial skin neoplasms that develop in photoexposed areas and can progress to invasive carcinoma. They are seen frequently in dermatological practice, occurring in 5.1% of consultations. Ingenol mebutate (IM) was recently approved in Brazil as a topical therapy for field cancerization in actinic keratosis. oBjeCtive: To evaluate the clearance rate and adverse events in the treatment of actinic keratoses with ingenol mebutate. Methods: A longitudinal, prospective, non-randomized, interventional, open, single-center study was conducted. Patients with actinic keratoses applied ingenol mebutate on a 25cm 2 area of the face and/or scalp for three consecutive days (0.015%) or on the forearm for two days (0.05%). results: 27 patients completed the protocol, of whom 13 on the face and/or scalp and 14 on the forearm. Complete clearance occurred in 53.8% in the first group and 42.8% in the second. Partial response was observed in 15.4% and 35.7%, respectively. The most common side effects were erythema, edema, desquamation, pruritus, and local erosion. study liMitations: The study had a small sample and was not randomized, double-blind, placebo-controlled, or vehiclecontrolled. ConClusion: Ingenol mebutate is well-tolerated for the treatment of actinic keratosis, with good patient adherence thanks to the short treatment period.
INTRODUCTION
Skin alterations in response to sun exposure have increased dramatically in the last 50 years due to population aging and increased exposure to ultraviolet (UV) radiation. 1 Solar keratosis, senile keratosis, or actinic keratosis (AK) are benign intraepithelial neoplasms, formed by atypical keratinocyte proliferation, common in photo-exposed areas. They comprise a significant share of dermatology practice and are considered the fourth most frequent diagnosis, occurring in 5.1% of patient consultations in Brazilian statistics for 2006. 2 AK mainly affects individuals with low phototypes and, increasingly, immunosuppressed individuals. 2 Secondary factors for the development of AK are advanced age, male gender, birthplace with higher UV index, Caucasoid ethnic group, previous history of cutaneous neoplasms, work history with sun exposure, and low socioeconomic status. 2, 3 Actinic keratosis results from the adverse effects of UV radiation on keratinocyte DNA, reducing the skin's immunity and thus allowing the lesion development. The mutations p16 (INK4a; 9p21), p14 (ARF), p15 (INK4b), and p53 are closely associated with increased risk of progression to squamous cell carcinoma (SCC). 4 Clinically, the lesions grow slowly and are characterized by erythematous papules, pigmented or not, that can be covered with yellowish or brownish scales, with little or no infiltration, measur-ing less than 1cm in diameter. The adjacent skin can show evidence of chronic sun damage with telangiectasias, elastosis, wrinkles, poikiloderma, and dyschromia. This new drug presents two mechanisms of action: rapid induction of cell death in the treated area a few hours after application and an inflammatory response in a few days after application, capable of eliminating the residual cells. 8 The keratinocyte's death appears to be related to necrosis through mitochondrial edema and chemoablation with rupture of the plasma membrane. The inflammatory response is caused by both the cell necrosis and activation of protein kinase C, capable of stimulating the release of proinflammatory cytokines, expression of endothelial adhesion molecules, and production of tumor-specific antibodies and leading to cytotoxicity mediated by antibody-dependent neutrophils. 8 The drug in gel form is available in two presentations, one at a concentration of 150μg/g for application on the target area of the face or scalp once a day for three consecutive days, and the other at 500μg/g for use on the trunk or extremities for two consecutive days. The tube's content should be applied on an affected area measuring a maximum of 25cm 2 .
The most common adverse reactions include erythema, desquamation, and formation of crusts. These reactions are most intense from the third to eighth day from initiation of treatment, with spontaneous improvement within two to four weeks. Edema, formation of pustules, erosion, and ulceration can also occur. There are no reports of scarring. 8, 9 Anderson et al. demonstrated statistically significant improvement in patients treated with IM when compared to controls (placebo) 57 days after initiating treatment. 9 There is growing interest in combined therapies for AKs, especially with the advent of new treatment options. However, the final choice of treatment should assess not only efficacy, but also the adverse reactions, aesthetic results, access, cost, and patient's choice. 4 This study aims to assess the clearance of lesions and the adverse events in the treatment of actinic keratoses with ingenol mebutate used on the face/scalp and limbs. On each treatment day, the tube's content was applied on an area measuring 25cm 2 , spread homogeneously, and left to dry for 15 minutes. Patients were instructed to wash their hands immediately after the application, not to touch the treated area for six hours or expose the area to sun, to store the tubes under refrigeration (2 to 8ºC) until their use, and to discard them after opening and use.
METHOD
Patients were assessed 7 days (D7) after initiating application of the medication, and photographic records were performed, along with analysis of adverse events (pain, local infection, edema, ulcer, pruritis, erythema, desquamation, and paresthesia).
Patients also returned at 57 days (D57) following initiation of treatment for the final evaluation and a new photographic record. 
RESULTS
Thirty-one patients were initially selected to participate in the study, of whom 15 patients were assigned to application on the face or scalp and 16 for application on the forearm. Three patients were eventually excluded from the study for not appearing on all the scheduled days, and one for not using the medication correctly. of the lesions (Figures 3 and 4 ). There was a mean reduction of 87.9%
compared to baseline in the number of AKs in the treated patients.
The most common adverse effects observed at D7 after application of ingenol mebutate were erythema, edema, desquamation, and pruritis at the application site, the majority of which were transient, with spontaneous resolution observed at D57, with persistent erythema in 28.6% of the patients and edema in 7.1%, as shown in table 2. AK, aimed at treatment of field cancerization. The different therapies that were analyzed (diclofenac 3%, 5-fluorouracil 0.5%, imiquimod 5%, and IM at 0.015% and 0.05%) showed similar efficacy but were associated with different cosmetic outcomes and adverse effects, with the following dropout rates: 144 of 1,000 participants in the group treated with diclofenac sodium in hyaluronic acid 2.5%; 40 of 1,000 participants using only hyaluronic acid 2.5%; and 56 of 1,000 using imiquimod 5%, compared to 21 of 1,000 patients that received placebo. The study did not report the dropout rate for patients that used IM. The authors suggested that more studies were needed to compare the various treatment modalities. 11 Sotiriou et al.
used photodynamic therapy with aminolevulinic acid for treatment of field cancerization and observed a 65.32% response rate in six months of follow-up for two treatment sessions. 12 Samorano et al.
found that local reactions with IM were less lasting when compared to 5-fluorouracil, but that both were safe and well-tolerated. 13 In our study, all the patients had adverse effects at D7, which were expected for the treatment. There was good tolerability, with 33.3% presenting prolonged adverse effects (erythema 25.9%, desquamation 7.4%, scaling 7.4%, pruritis 7.4%, periorbital edema 3.7%, and hypochromia 3.7%), none of which were considered serious. The persistence of these effects had already been observed in a previous study, showing alterations in pigmentation in all the study groups, besides minimal scarring. 8 Patients treated with IM that presented higher grade inflammation resulting from the medication ap- Figure 4 : D1, D7, and D57 on forearm treated for two days with IM 0.05%. On D1 there were six AK lesions, while on D57 there was one lesion. On D7, moderate erythema, desquamation, crusting pear to have evolved with more significant clinical improvement of the treated area, based on aesthetic and therapeutic improvement, but more studies are necessary.
As for dosage, we observed high treatment adherence, since 90% of patients completed treatment, appearing for follow-up at both D7 and D57, which had been reported previously by Matin and Swanson. 14 The dosing schedule can be advantageous when compared to other drugs, since it requires shorter treatment times, and the adverse effects only began after completing the prescribed treatment regimen. It is thus recommended to apply the product in the physician's office or clinic in order to avoid inadequate use of the medication. The main advantage of treatment with ingenol mebutate is that similar degrees of efficacy can be achieved with only two or three days of treatment. 8 The study had the following limitations: low number of patients, lack of blinding, lack of placebo control, no direct comparison with other medications, and lack of follow-up at one year. Neither did the study assess the reasons for patients' failure to appear on the scheduled days, and no biopsies were performed to prove the diagnosis prior to treatment, nor after treatment to prove clinical improvement. Since the treatment was performed on exposed areas like the face, we opted to perform diagnostic and follow-up exclusively according to clinical and dermoscopic criteria. Since the study was not a randomized clinical trial, it did not assess efficacy and safety, but it does corroborate some findings already published in the world literature.
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CONCLUSION
Patients that used ingenol mebutate showed good clearance of the lesions and foreseeable adverse events. The short treatment period appears to have facilitated patients' adherence. We thus conclude that IM can be an option in the therapeutic armamentarium for AK. q
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